TD Cowen raised the firm’s price target on Sarepta to $165 from $135 and keeps an Outperform rating on the shares. The firm noted the FDA accepted the company’s Elevidys sBLA with Priority Review for label expansion to all DMD points without age or ambulation restrictions, and conversion of accelerated to full approval. The PDUFA is June 21st with no AdComm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRPT:
- Sarepta price target raised to $169 from $164 at BofA
- Sarepta Priority Review confirms FDA ‘amenability to approval,’ says RBC Capital
- Sarepta announces FDA acceptance of efficacy supplement to Elevidys BLA
- Sarepta price target raised to $145 from $130 at Mizuho
- Sarepta price target raised to $160 from $113 at Citi
